Related Experiment Video
Updated: Aug 11, 2026
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
Published on: September 15, 2010
Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy
H Kasuya1, M Mizuno, J Yoshida
1Department of Surgery II, Nagoya University School of Medicine, Japan.
Background And Objectives:
Although surgical therapy for pancreatic cancer has not been successful, new gene therapies, such as adeno-associated virus (AAV) vectors hold promise for treating cancer. However, expression of AAV vectors alone is insufficient for adequate effects in vivo for cancer therapy. We describe a novel therapy using the combined herpes simplex virus-ICP6 deletion mutant (ICP6delta) and AAV vector.
Methods:
We investigated ICP6delta and AAV regarding kinetics and dose-response relationships of LacZ expression in vitro. We studied the expression of LacZ in vivo using subcutaneous pancreatic cancer tumors (SW1990) in nude mice.
Results:
In vitro, ICP6delta enhanced the expression of AAV; 24 hr following inoculation there was more expression with AAV plus ICP6delta than with AAV plus KOS, and a multiplicity of infection (MOI) of 0.5 was the optimal titer of ICP6delta to support maximal expression of AAV. In vivo, there was much higher expression of LacZ in mice injected with AAV-LacZ plus ICP6A than with AAV-LacZ alone.
Conclusions:
ICP6delta enhances expression of AAV-vector in vitro and in vivo. These results suggested that combined therapy have potential for human cancer.
Insights
A novel gene therapy combining adeno-associated virus (AAV) vectors with herpes simplex virus-ICP6 deletion mutant (ICP6delta) significantly enhances gene expression in pancreatic cancer models, showing promise for future cancer treatments.
Area of Science:
- Oncolytic virotherapy
- Gene therapy delivery systems
Background:
- Pancreatic cancer treatment remains challenging with limited surgical success.
- Adeno-associated virus (AAV) vectors show promise but require enhanced efficacy for in vivo cancer therapy.
- A novel combination therapy using AAV vectors and a herpes simplex virus mutant is explored.
Purpose of the Study:
- To investigate the synergistic effects of ICP6delta and AAV vectors on gene expression.
- To determine the optimal conditions for combined AAV and ICP6delta therapy.
- To evaluate the efficacy of this combined therapy in a pancreatic cancer model.
Main Methods:
- In vitro studies assessed LacZ expression kinetics and dose-response with ICP6delta and AAV.
- In vivo experiments utilized subcutaneous pancreatic tumors (SW1990) in nude mice to study LacZ expression.
- Optimal multiplicity of infection (MOI) for ICP6delta was determined to maximize AAV expression.
Main Results:
- ICP6delta significantly enhanced AAV-mediated LacZ expression in vitro.
- An MOI of 0.5 for ICP6delta was found to be optimal for maximal AAV expression.
- In vivo studies demonstrated substantially higher LacZ expression in tumors treated with AAV-LacZ plus ICP6delta compared to AAV-LacZ alone.
Conclusions:
- ICP6delta acts as an effective enhancer for AAV vectors both in vitro and in vivo.
- The combined AAV-ICP6delta therapy presents a promising strategy for human cancer treatment.
- This approach could overcome limitations of current AAV-based gene therapies for pancreatic cancer.
Related Concept Videos
01:51Mechanisms of Retrovirus-induced Cancers
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...